Insmed, Inc. (NASDAQ:INSM) Given Average Rating of “Moderate Buy” by Analysts

Insmed, Inc. (NASDAQ:INSM) has earned a consensus recommendation of “Moderate Buy” from the twenty-four brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twenty have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $205.4091.

A number of research firms have commented on INSM. Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a research note on Thursday, December 4th. Wolfe Research set a $167.00 price objective on shares of Insmed and gave the company an “outperform” rating in a research report on Thursday. Cantor Fitzgerald raised their target price on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. The Goldman Sachs Group lifted their price target on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th.

Insmed Stock Up 0.5%

Shares of Insmed stock opened at $175.76 on Tuesday. Insmed has a 1 year low of $60.40 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The company has a market capitalization of $37.48 billion, a P/E ratio of -28.39 and a beta of 1.01. The business has a 50-day moving average of $187.90 and a two-hundred day moving average of $144.73.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.27) EPS. As a group, equities analysts predict that Insmed will post -4.56 EPS for the current year.

Insider Activity

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $166.97, for a total transaction of $1,786,412.03. Following the transaction, the chief executive officer directly owned 303,911 shares of the company’s stock, valued at $50,744,019.67. This represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider owned 54,902 shares of the company’s stock, valued at $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 157,829 shares of company stock valued at $30,266,463. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares in the last quarter. Norges Bank bought a new stake in Insmed during the 2nd quarter valued at $194,728,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Insmed by 109.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new position in shares of Insmed in the second quarter worth $153,389,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.